Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/306354

Lähdeviite

Tikkanen , E , Minicocci , I , Hällfors , J , Di Costanzo , A , D'Erasmo , L , Poggiogalle , E , Donini , L M , Wurtz , P , Jauhiainen , M , Olkkonen , V M & Arca , M 2019 , ' Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State ' , Arteriosclerosis, Thrombosis, and Vascular Biology , vol. 39 , no. 4 , pp. 665-674 . https://doi.org/10.1161/ATVBAHA.118.312021

Julkaisun nimi: Metabolomic Signature of Angiopoietin-Like Protein 3 Deficiency in Fasting and Postprandial State
Tekijä: Tikkanen, Emmi; Minicocci, Ilenia; Hällfors, Jenni; Di Costanzo, Alessia; D'Erasmo, Laura; Poggiogalle, Eleonora; Donini, Lorenzo Maria; Wurtz, Peter; Jauhiainen, Matti; Olkkonen, Vesa M.; Arca, Marcello
Tekijän organisaatio: Medicum
University Management
Department of Anatomy
University of Helsinki
Päiväys: 2019-04
Kieli: eng
Sivumäärä: 10
Kuuluu julkaisusarjaan: Arteriosclerosis, Thrombosis, and Vascular Biology
ISSN: 1079-5642
DOI-tunniste: https://doi.org/10.1161/ATVBAHA.118.312021
URI: http://hdl.handle.net/10138/306354
Tiivistelmä: Objective- Loss-of-function (LOF) variants in the ANGPTL3 (angiopoietin-like protein 3) have been associated with low levels of plasma lipoproteins and decreased coronary artery disease risk. We aimed to determine detailed metabolic effects of genetically induced ANGPTL3 deficiency in fasting and postprandial state. Approach and Results- We studied individuals carrying S17X LOF mutation in ANGPTL3 (6 homozygous and 32 heterozygous carriers) and 38 noncarriers. Nuclear magnetic resonance metabolomics was used to quantify 225 circulating metabolic measures. We compared metabolic differences between LOF carriers and noncarriers in fasting state and after a high-fat meal. In fasting, ANGPTL3 deficiency was characterized by similar extent of reductions in LDL (low-density lipoprotein) cholesterol (0.74 SD units lower concentration per LOF allele [95% CI, 0.42-1.06]) as observed for many TRL (triglyceride-rich lipoprotein) measures, including VLDL (very-low-density lipoprotein) cholesterol (0.75 [95% CI, 0.45-1.05]). Within most lipoprotein subclasses, absolute levels of cholesterol were decreased more than triglycerides, resulting in the relative proportion of cholesterol being reduced within TRLs and their remnants. Further, beta-hydroxybutyrate was elevated (0.55 [95% CI, 0.21-0.89]). Homozygous ANGPTL3 LOF carriers showed essentially no postprandial increase in TRLs and fatty acids, without evidence for adverse compensatory metabolic effects. Conclusions- In addition to overall triglyceride- and LDL cholesterol-lowering effects, ANGPTL3 deficiency results in reduction of cholesterol proportion within TRLs and their remnants. Further, ANGPTL3 LOF carriers had elevated ketone body production, suggesting enhanced hepatic fatty acid beta-oxidation. The detailed metabolic profile in human knockouts of ANGPTL3 reinforces inactivation of ANGPTL3 as a promising therapeutic target for decreasing cardiovascular risk.
Avainsanat: biomarkers
fasting
humans
lipoproteins
metabolomics
FAMILIAL COMBINED HYPOLIPIDEMIA
GENETIC INHIBITION
ANGPTL3 GENE
MUTATIONS
RISK
TRIGLYCERIDES
EPIDEMIOLOGY
LIPOPROTEINS
LIPIDS
3121 General medicine, internal medicine and other clinical medicine
Vertaisarvioitu: Kyllä
Pääsyrajoitteet: openAccess
Rinnakkaistallennettu versio: publishedVersion


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
ATVBAHA.118.312021.pdf 1.209MB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot